Phase II Study to Evaluate the Efficacy and Safety of Intravenous Palonosetron in Primary Glioma Patients Receiving Standard Radiotherapy and Concomitant Temozolomide.

Trial Profile

Phase II Study to Evaluate the Efficacy and Safety of Intravenous Palonosetron in Primary Glioma Patients Receiving Standard Radiotherapy and Concomitant Temozolomide.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 May 2014

At a glance

  • Drugs Palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting; Radiotherapy-induced nausea and vomiting
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jun 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 28 Jun 2011 Planned end date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top